Which biologic binds circulating IgE and requires a post-injection observation period due to anaphylaxis risk?
Choose an answer, then check it.
Clinical Pharmacology · Respiratory Medications
Respiratory Biologics
On this page 6 sections
In 30 seconds
Respiratory biologics are injectable monoclonal antibodies added on top of standard inhaler therapy for severe asthma that stays uncontrolled despite high-dose inhaled corticosteroids plus another controller. Each agent blocks one specific molecule in the allergic or eosinophilic inflammatory pathway rather than acting broadly like steroids. Choosing among them depends on phenotype, guided by blood eosinophil count, IgE level, and allergen sensitization history. The shared goals are fewer exacerbations, better control, and reduced reliance on chronic oral corticosteroids.
The college version
The add-on framework
Severe asthma biologics are never first-line; they enter only after symptoms or flares persist despite maximized inhaled therapy and confirmed adherence. Because they are costly and specialty-administered, phenotyping matters: clinicians use blood eosinophil count, total IgE with allergen sensitization, and clues like nasal polyps or atopic dermatitis to match the patient to the likely driving pathway.
IgE-directed therapy
Omalizumab binds circulating IgE, preventing it from triggering mast cell and basophil degranulation in allergic asthma confirmed by IgE testing and sensitization. It is given subcutaneously. Its signature concern is anaphylaxis, which can occur even after prior uneventful doses, so a post-injection observation period is required.
Anti-IL-5 pathway agents
Mepolizumab and reslizumab bind interleukin-5 itself, while benralizumab binds the IL-5 receptor and promotes eosinophil depletion by a different mechanism. All three target eosinophilic asthma. Mepolizumab and benralizumab are subcutaneous, some suitable for self-injection; reslizumab is intravenous. Because eosinophils help defend against parasites, prescribers must address any pre-existing helminth infection before starting anti-IL-5 therapy, since suppressing eosinophils could let such an infection worsen.
Dupilumab: a dual-cytokine blocker
Dupilumab targets the IL-4 receptor alpha subunit, shared by both the IL-4 and IL-13 receptors, so one drug interrupts two overlapping type 2 signals at once. This explains its use beyond asthma, including atopic dermatitis and chronic rhinosinusitis with nasal polyps, useful for overlapping atopic disease. It is subcutaneous. Safety points include injection site reactions and a transient, usually asymptomatic rise in blood eosinophil count that is monitored.
Tezepelumab: an upstream, phenotype-agnostic option
Tezepelumab targets thymic stromal lymphopoietin, an epithelial alarmin released by airway cells before the downstream cascade begins. Acting further upstream than the other agents, it shows efficacy across a broader range of phenotypes, including patients who don't fit neatly into IgE- or eosinophil-driven categories. It is subcutaneous; headache is a commonly reported effect.
Practical realities
All these agents are given by injection at set intervals; some are designed for home self-injection while others require infusion visits. Cost is substantial, and insurer prior authorization is a routine, often lengthy barrier to starting or continuing therapy, making biologic selection as much a logistical decision as a pharmacologic one.
Eli explains
The same idea, in plain words
Explain it like I’m 10
Imagine severe asthma is a house alarm that keeps going off even after every door and window is locked (that's the inhalers). These biologic shots don't lock more doors — they go straight to the alarm's wiring and disconnect one specific wire that keeps setting it off. Different people's alarms get triggered by different wires: pollen dust (the IgE wire, blocked by omalizumab), a troublemaking alarm cell called an eosinophil (blocked by the anti-IL-5 shots), a wire two signals share at once (dupilumab), or the very first sensor that notices trouble at all (tezepelumab, which works earliest). Doctors test which wire is causing the problem before picking a shot. The catch is these shots are pricey, need insurance approval first, and each carries its own small risks to watch for.
Check yourself
2 review questions from the chapter. Try each one, then open the answer.
A patient has severe asthma with a normal eosinophil count and no clear allergic trigger, yet remains uncontrolled on maximal inhaled therapy. Why might tezepelumab be considered before some of the other biologics?
Show answer
Tezepelumab targets TSLP, an alarm signal released before the eosinophil or IgE pathways even activate, so it can help phenotypes that don't fit neatly into "high eosinophil" or "high IgE" categories.
This makes it a reasonable option when biomarkers don't clearly point toward one pathway-driven drug.
A nursing student asks why insurance prior authorization is a clinically relevant topic rather than just an administrative detail. Give a brief explanation.
Show answer
Prior authorization can delay or block a medication that meaningfully reduces exacerbations and steroid exposure, so it affects real clinical outcomes, not just paperwork.
A nurse who understands this can better advocate for timely approval and set realistic expectations with patients.
Quick check
3 questions here. Answers stay hidden until you check.
Dupilumab blocks a receptor subunit shared by which two cytokines?
Choose an answer, then check it.
Before starting an anti-IL-5 pathway agent, a clinician should specifically evaluate for which condition?
Choose an answer, then check it.
Study tools & related lessonsRelated
Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.